Epidemic response to COVID-19 in pharmaceutical and healthcare industries series - Issue 1

Pharmaceutical and medical device companies are taking a variety of proactive measures to deal with this outbreak in the areas of R&D registration, production and supply chain and marketing. And a number of patient centric digital innovations have emerged from disease diagnosis and consultation, drug discovery and delivery, patient and public education and patient information management.

Contact us

Mark Gilbraith

China Consulting, Consumer, Health and Technology Industry Leader, PwC China

Tel: +[86] (21) 2323 2898

Jia Xu

Pharma and Healthcare Consulting Leader, PwC China

Tel: +[86] (10) 6533 7734

Jingyu Cai

Partner, PwC China

Tel: +[86] (21) 2323 3005

Follow us